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EVIDENCE-BASED ANSWER
A
Q Do ACE inhibitors or ARBs help 
prevent kidney disease in patients 
with diabetes and normal BP?
 Yes for angiotensin-converting 
 enzyme (ACE) inhibitors, no for 
angiotensin receptor blockers (ARBs). 
In normotensive patients with type 
1 and type 2 diabetes, ACE inhibitor ther-
apy reduces the risk of developing dia-
betic kidney disease, defined as new-onset 
microalbuminuria or macroalbuminuria, 
by 18% (strength of recommendation [SOR]: 
C, meta-analysis of randomized controlled 
trials [RCTs], disease-oriented evidence). 
ACE inhibitor treatment improves all-
cause mortality by 16% in patients with 
diabetes, including patients with and with-
out hypertension. Patients on ACE inhibi-
tor therapy are at increased risk of cough 
(SOR: A, meta-analysis of RCTs).
ARB therapy doesn’t lower the risk of 
developing kidney disease in normoten-
sive patients with type 2 diabetes (SOR: C, 
meta-analysis of RCTs, disease-oriented 
evidence); nor does it reduce all-cause mor-
tality in patients with or without hyperten-
sion (SOR: A, meta-analysis of RCTs). ARBs 
aren’t associated with significant adverse 
events (SOR: A, meta-analysis of RCTs).
Evidence summary
A 2011 meta-analysis of 5 RCTs (total 2975 
patients) that compared ACE inhibitor ther-
apy with placebo in diabetic patients without 
hypertension and albuminuria found that 
ACE inhibitors reduced the risk of new-onset 
microalbuminuria or macroalbuminuria by 
18% (relative risk [RR]=0.82; 95% confidence 
interval [CI], 0.73-0.92).1 Normal albumin-
uria was defined in all included studies as an 
albumin excretion rate of <30 mg/d on a 
timed specimen confirmed with 3 serial 
measurements.
The RCTs included patients treated with 
lisinopril, enalapril, and perindopril. All but 
one examined patients with type 1 diabetes 
(2781 patients). The study that evaluated type 
2 diabetes (194 patients) assessed patients 
with hypertension who used other antihy-
pertensives to achieve normal blood pres-
sure targets before ACE inhibitor initiation, a 
potential limitation. 
Compared with placebo or no treat-
ment, ACE inhibitor therapy reduced the 
risk of death from any cause (6 studies; 
11,350 patients; RR=0.84; 95% CI, 0.73-
0.97).1 Patient populations across pooled 
RCTs were heterogeneous, including sub-
jects with type 1 and type 2 diabetes, with 
or without hypertension, and with or with-
out albuminuria. 
ACE inhibitors increase risk of cough
Patients taking an ACE inhibitor have an 
increased risk of cough (6 studies; 11,791 
patients; RR=1.84; 95% CI, 1.24-2.72).1 ACE 
inhibitor therapy doesn’t increase the risk of 
headache or hyperkalemia.
ARBs don’t help prevent diabetic kidney 
disease in normotensive patients
The 2011 meta-analysis also included 5 RCTs 
(4604 patients, approximately 3000 with type 
2 diabetes and more than 1000 with type 
1 diabetes) that compared ARBs with placebo 
in patients without hypertension.1 Unlike 
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ACE inhibitor therapy, ARB treatment didn’t 
significantly affect new-onset microalbumin-
uria or macroalbuminuria (RR=1.06; 95% CI, 
0.67-1.69).
The trials evaluated losartan, candes-
artan, olmesartan, and valsartan. One study 
used other antihypertensives to achieve tar-
get blood pressure, and another included 
patients of any albuminuria status.
Compared with placebo or no treat-
ment, ARBs didn’t reduce the risk of death 
(5 studies; 7653 patients; RR=1.12; 95% CI, 
0.88-1.41).1 All 5 RCTs assessed normoal-
buminuric patients. Three of the 5 studies 
examined normotensive patients; one evalu-
ated only hypertensive patients, and another 
assessed mostly hypertensive patients.
ARBs usually don’t produce  
significant adverse effects
Within the meta-analysis, ARBs didn’t 
increase risk of cough, headache, or 
hyperkalemia.1                  JFP
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